INT178498

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2004
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 4.21
Pain Relevance 0.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Fgf2) signal transduction (Fgf2) extracellular space (Fgf2)
extracellular region (Fgf2) nucleus (Fgf2) embryo development (Fgf2)
Anatomy Link Frequency
fat 1
spinal cord 1
fibroblast 1
astrocyte 1
neural 1
Fgf2 (Mus musculus)
Pain Link Frequency Relevance Heat
Spinal cord 101 100.00 Very High Very High Very High
cINOD 3 99.12 Very High Very High Very High
cytokine 21 96.86 Very High Very High Very High
Inflammation 36 80.40 Quite High
cva 6 71.88 Quite High
Central nervous system 42 71.76 Quite High
medulla 30 70.00 Quite High
Spinal nerve ligature 2 51.20 Quite High
withdrawal 23 49.92 Quite Low
psoriasis 1 48.68 Quite Low
Disease Link Frequency Relevance Heat
Spinal Cord Injury 24 100.00 Very High Very High Very High
Cancer 285 99.52 Very High Very High Very High
INFLAMMATION 67 98.84 Very High Very High Very High
Adenocarcinoma 6 97.52 Very High Very High Very High
Apoptosis 145 96.40 Very High Very High Very High
Lung Cancer 6 94.44 High High
Neurodegenerative Disease 8 91.60 High High
Intestinal Polyposis 1 89.32 High High
Bladder Cancer 1 89.00 High High
Leukemia 8 88.00 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
FGF-2 Labeling intensity in GFAP-positive and GFAP-negative cells
Negative_regulation (intensity) of FGF-2
1) Confidence 0.42 Published 2010 Journal Frontiers in Cellular Neuroscience Section Body Doc Link PMC2990542 Disease Relevance 0 Pain Relevance 0.14
Our findings support these results, where FGF-2 immunoreactivity was found in large amounts, at the first week, after spinal cord injury, and significantly decreased during the second week in SC3.
Negative_regulation (decreased) of FGF-2 in spinal cord associated with spinal cord
2) Confidence 0.42 Published 2010 Journal Frontiers in Cellular Neuroscience Section Body Doc Link PMC2990542 Disease Relevance 0.26 Pain Relevance 0.31
When the CholAB – treated cultures were forced to differentiate (by removal of FGF2, CholAB, and the addition of B27 cell culture supplement and neurotrophins for 7 days), neurons, astrocytes, and oligodendrocytes were generated (Figure 5c), showing that the potential of the culture en masse to generate all three major lineages of neural tissue was not lost.
Negative_regulation (removal) of FGF2 in neural
3) Confidence 0.32 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2877108 Disease Relevance 0 Pain Relevance 0
The VEGF inhibitor, bFGF inhibitor and PDGF inhibitor each reduced HUVEC proliferation significantly, whereas either a combination of the 3 inhibitors together or wortmannin alone abolished HUVEC proliferation.
Negative_regulation (inhibitor) of bFGF
4) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0.26 Pain Relevance 0.04
The cultured HUVECs were treated with or without 100 IU/ml EPO for 48 hours, and then exposed for 3 hours to (a) 0.25 mg/ml bevacizumab, (b) 100 nM of PD173074; an inhibitor of bFGF (Calbiochem, San Diego, CA), (c) 20 µM of tyrphostin AG 1296; a selective inhibitor of PDGF (sigma), (d) a combination of bevacizumab, PD173074 and tyrphostin, and to (e) 100 nM wortmannin; a phosphatidylinositol 3-kinaz (PI 3-K) inhibitor (sigma).
Negative_regulation (inhibitor) of bFGF
5) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0 Pain Relevance 0
Furthermore, EPO normalized in vitro HUVEC proliferation in the presence of a single growth factor inhibitor such as bevacizumab (VEGF inhibitor), PD173074 (bFGF inhibitor) or tyrphostin (PDGF inhibitor), strengthening our claim that the use of one growth factor for fat tissue vascularization might not be adequate.
Negative_regulation (inhibitor) of bFGF in fat
6) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0.14 Pain Relevance 0
Simultaneous removal of EGF and FGF-2 on laminin results in astrocyte differentiation (unpublished data).
Negative_regulation (removal) of FGF-2 in astrocyte
7) Confidence 0.24 Published 2005 Journal PLoS Biology Section Body Doc Link PMC1184591 Disease Relevance 0.51 Pain Relevance 0
Upon passaging, these cells did not persist in FGF-2 alone, but in FGF-2 plus EGF they proliferated in the absence of other cell types.
Neg (not) Negative_regulation (persist) of FGF-2
8) Confidence 0.24 Published 2005 Journal PLoS Biology Section Body Doc Link PMC1184591 Disease Relevance 0 Pain Relevance 0
Upon passaging, these cells did not persist in FGF-2 alone, but in FGF-2 plus EGF they proliferated in the absence of other cell types.
Neg (not) Negative_regulation (persist) of FGF-2
9) Confidence 0.24 Published 2005 Journal PLoS Biology Section Body Doc Link PMC1184591 Disease Relevance 0 Pain Relevance 0
In contrast, COX-2 is an early response gene induced by growth factors, proinflammatory cytokines, tumour promoters and bacterial toxins.9–11 Inhibition of COX-2 by non-steroidal anti-inflammatory drugs (NSAIDs) results in inhibition of angiogenesis and downregulation of angiogenic factors such as VEGF and bFGF-2 (basic fibroblast growth factor).12–14 In human colorectal adenocarcinoma and other malignancies such as breast, cervical, prostate and lung tumours, increased COX-2 expression has been reported.15 16 In mice, inhibition of COX-2 has been shown to protect against intestinal polyposis.17 The precise mechanisms whereby COX-2 contributes to tumourigenesis include effects on the epithelium, but additional effects on non-epithelial populations including the microvascular endothelium have also been suggested.11
Negative_regulation (downregulation) of bFGF in fibroblast associated with adenocarcinoma, intestinal polyposis, lung cancer, inflammation, cancer, cinod and cytokine
10) Confidence 0.18 Published 2008 Journal Gut Section Body Doc Link PMC2582343 Disease Relevance 1.26 Pain Relevance 0.32
PTTG1 siRNA was successful in downregulating PTTG1 as well as Ki67, bFGF, and CD34 in H1299 tumors in nude mice.
Negative_regulation (downregulating) of bFGF associated with cancer
11) Confidence 0.13 Published 2008 Journal J Ovarian Res Section Body Doc Link PMC2584053 Disease Relevance 0.67 Pain Relevance 0
Inhibition of bFGF is the primary pro-angiogenic factor that has been implicated [92].
Negative_regulation (Inhibition) of bFGF
12) Confidence 0.12 Published 2004 Journal J Transl Med Section Body Doc Link PMC455695 Disease Relevance 1.12 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox